Effects of Hyperlipidemia on the Pharmacokinetics of Tofacitinib, a JAK 1/3 Inhibitor, in Rats

Tofacitinib, an inhibitor of Janus kinases (JAKs) 1 and 3, has been shown to be effective in the treatment of rheumatoid arthritis. The incidence of hyperlipidemia has been found to be higher in patients with rheumatoid arthritis. The present study therefore investigated the pharmacokinetics of tofa...

Descripción completa

Detalles Bibliográficos
Autores principales: Won, Jong Mun, Choi, Hyeon Gyeom, Park, So Yeon, Kim, Jang-Hee, Kim, So Hee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10534486/
https://www.ncbi.nlm.nih.gov/pubmed/37765165
http://dx.doi.org/10.3390/pharmaceutics15092195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10534486/
https://www.ncbi.nlm.nih.gov/pubmed/37765165
http://dx.doi.org/10.3390/pharmaceutics15092195

Ejemplares similares